症狀性神經源性姿勢性低血壓（SnOH）：市場展望、流行病學、競爭格局和市場預測報告，2025-2035年

市場概覽

• 德國 SnOH 市場預計將從 2025 年的 900 萬美元成長到 2035 年的 1,100 萬美元，這反映了其小規模穩定的患者群體所伴隨的逐步成長。
• 市場擴張受限的主要原因如下：
• 擴大現有治療方法（Midodrine、屈昔多巴等）的應用範圍
• 診斷和治療率逐步提高
• 該市場仍受到疾病認知度低、診斷不足和治療方案創新有限等因素的限制。
• 未來的成長取決於提高對疾病的認知，並開發更有效的治療方法，以控制症狀並解決潛在的自主神經功能障礙。

症狀性神經源性姿勢性低血壓（SnOH）概述

症狀性神經源性姿勢性低血壓（SnOH）是一種慢性自主神經功能障礙，會損害身體機能。其特徵是站立時血壓持續下降（收縮壓≥20 mmHg，或舒張壓≥10 mmHg），這是由於自主神經病變系統調節功能受損所致。此疾病是由交感神經元釋放去甲腎上腺素不足引起的，導致體位改變時血管張力和腦血流量無法維持。

臨床上，SnOH 表現為腦缺血症狀，包括頭暈、頭暈、暈厥、視力障礙以及特徵性的「衣架樣」頸肩疼痛。此病常與巴金森氏症和其他突觸核蛋白病等神經退化性疾病以及周邊自主神經病變有關。

治療方案複雜，需要在緩解姿勢性低血壓症狀和最大限度降低臥位高血​​壓加重風險之間取得平衡。治療方案採用階梯式方法，首先進行非藥物治療（例如，補充液體和鹽分、穿戴壓力衣），然後使用藥物治療，例如ludrocortisone、Midodrine和屈昔多巴，以改善血管張力和循環血容量。儘管有多種治療方法，但許多患者的症狀控制仍然不足，這種疾病嚴重影響患者的生活品質和功能獨立性。

主要亮點

• 在法國，中度至重度 SnOH 病例數預計將從 2025 年的 11,000 例增加到 2035 年的 11,200 例，增幅非常小（複合年成長率為 0.2%），反映出患者群體相對穩定。
• 持續存在的症狀和對現有治療的不完全反應表明，仍然迫切需要更有效、更持久的治療方案。
• 尤其是在老齡化社會和神經退化性疾病，隨著人們意識的提高和診斷技術的進步，預計患者識別將逐步改善。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• CuraSen Therapeutics
• Theravance Biopharma

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Symptomatic Neurogenic Orthostatic Hypotension (SnOH) Market Outlook

Thelansis's "Symptomatic Neurogenic Orthostatic Hypotension (SnOH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Symptomatic Neurogenic Orthostatic Hypotension treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Symptomatic Neurogenic Orthostatic Hypotension (SnOH) Overview

Symptomatic Neurogenic Orthostatic Hypotension (SnOH) is a chronic and debilitating autonomic disorder characterized by a sustained drop in blood pressure upon standing (>=20 mmHg systolic or >=10 mmHg diastolic) due to impaired autonomic regulation. The condition arises from inadequate norepinephrine release from sympathetic neurons, resulting in failure to maintain vascular tone and cerebral perfusion during postural changes.

Clinically, SnOH presents with symptoms of cerebral hypoperfusion, including dizziness, lightheadedness, syncope, visual disturbances, and the characteristic "coat-hanger" neck and shoulder pain. It is commonly associated with neurodegenerative disorders such as Parkinson's Disease and other synucleinopathies, as well as peripheral autonomic neuropathies.

Management is complex and requires careful balancing of orthostatic symptom relief with the risk of exacerbating supine hypertension. The treatment paradigm follows a stepwise approach, beginning with non-pharmacological interventions (e.g., fluid and salt loading, compression garments), followed by pharmacological therapies such as fludrocortisone, midodrine, and droxidopa to improve vascular tone and circulating volume. Despite available therapies, symptom control remains suboptimal in many patients, and the condition significantly impacts quality of life and functional independence.

Key Highlights

• In France, moderate-to-severe SnOH cases are projected to increase from 11.0K in 2025 to 11.2K by 2035, reflecting minimal growth (0.2% CAGR) and a relatively stable patient population.
• Persistent symptoms and incomplete response to existing therapies highlight a continued unmet need for more effective and durable treatment options.
• Increasing awareness and improved diagnosis, particularly in aging populations and neurodegenerative conditions, are expected to support gradual patient identification.

Market Overview

• The Germany SnOH market is projected to grow from $9M in 2025 to $11M by 2035, reflecting modest growth in line with a small and stable patient population.
• Limited market expansion is primarily driven by:
• Incremental uptake of existing therapies (e.g., midodrine, droxidopa)
• Gradual improvements in diagnosis and treatment rates
• The market remains constrained by low disease awareness, underdiagnosis, and limited innovation in therapeutic options.
• Future growth will depend on improved disease recognition and the development of more effective therapies addressing both symptomatic control and underlying autonomic dysfunction.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• CuraSen Therapeutics
• Theravance Biopharma

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)